Abstract:Background CXCL12 is a vital factor in physiological and pathological processes, by inducing migration of multiple cells. We aimed to comprehensively detect the role of CXCL12 in breast cancer, and explore novel CXCL12-related biomarkers through integrative multi-omics analyses to build a powerful prognostic model for breast cancer patients. Methods Immunohistochemistry analysis of the tissue microarray was performed to evaluate the correlation between CXCL12 expression levels and breast cancer patient outcomes. Combined single-nucleus and spatial transcriptomics data was used to uncover the expression distribution of CXCL12 in breast cancer microenvironment. CXCL12-related genes were identified by WGCNA analysis. Univariate Cox and LASSO regression analyses were then conducted to screen prognostic genes from above CXCL12-related genes, followed by the construction of the CXCL12-related prognostic signature, identification of risk groups, and external validation of the prognostic signature. Analyses of biological function, mutation landscape, immune checkpoint genes and immune cells, were performed to further reveal the differences between high/low-risk groups. Paired single-cell RNA-seq and bulk RNA-seq were analyzed to further disclose the association between the risk score and the complex tumor immune microenvironment. To screen potential therapeutic agents for breast cancer patients, analyses of gene-drug correlation and sensitivity to immunotherapy were conducted. Results High expression of CXCL12 was linked with a prolonged survival in breast cancer. A total of 402 genes were identified by WGCNA analysis and 11 genes, covering VAT1L, TMEM92, SDC1, RORB, PCSK9, NRN1, NACAD, JPH3, GJA1, BMP8B and ADAMTS2 , were screened as the candidate prognostic genes. Next, the prognostic signature was built and validated using these genes to predict the outcomes of breast cancers. The high-risk group patients exhibited significantly inferior prognoses. The combination of the risk score and tumor mutational burden (TMB) had remarkably improved performance in predicting patient outcomes. Besides, high-risk group patients showed higher infiltration of M2-like macrophages. Finally, several potential anticancer drugs were identified. The high-risk group patients were more sensitive to immunotherapy but resistant to docetaxel. Conclusions CXCL12 has important immunological implication and prognostic significance in breast cancer. The CXCL12-related prognostic model could well predict the prognosis and treatment response of breast cancers.

Upregulation of CXC chemokine receptor 4-CXC chemokine ligand 12 axis ininvasive breast carcinoma: A potent biomarker predicting lymph node metastasis

Recombination of CXCR4, VEGF, and MMP-9 predicting lymph node metastasis in human breast cancer.

A S100A14-CCL2/CXCL5 signaling axis drives breast cancer metastasis

Fibroblast-derived CXCL12 promotes breast cancer metastasis by facilitating tumor cell intravasation

The Impact of Chemokine Receptor CXCR4 on Breast Cancer Prognosis: A Meta-Analysis

The role of CXC chemokine ligand 4/CXC chemokine receptor 3-B in breast cancer progression

Integrative multi-omics analyses unravel the immunological implication and prognostic significance of CXCL12 in breast cancer

Study of CCL28 expression in breast cancer

Expression and Clinical Significance of the CXC Chemokine Receptor-4 (CXCR4) in Breast Cancer

The Role and Clinical Significance of the CXCL17-CXCR8 (GPR35) Axis in Breast Cancer

Upregulation of CXCR4 is essential for HER2-mediated tumor metastasis

Involvement of a novel chemokine decoy receptor CCX-CKR in breast cancer growth, metastasis and patient survival.

High CXC chemokine receptor 1 level represents an independent negative prognosticator in non-metastatic clear-cell renal cell carcinoma patients.

The chemokine receptor CCR4 promotes tumor growth and lung metastasis in breast cancer

Relationship between the CXC Chemokine Receptor-4 /CXCL12 Signal Transduction Pathway and Lymph Node Metastasis of Gastric Carcinoma

Chemokine axes CXCL12/CXCR4 and CXCL16/CXCR6 correlate with lymph node metastasis in epithelial ovarian carcinoma

An Emerging and Previously Unrecognized Paradigm of Cxcl12/Cxcr4 Pathway Implication in Breast Cancer Metastasis

Data from the CXCL12–CXCR4 Chemokine Pathway: A Novel Axis Regulates Lymphangiogenesis

Involvement of chemokine receptors in breast cancer metastasis

The CXCL12-CXCR4 chemokine pathway: a novel axis regulates lymphangiogenesis.

Analysis of C-X-C motif chemokine receptors in breast cancer: potential value in immunotherapy and prognostic prediction